SpringWorks Therapeutics Analysis: $3.5B Raised

Treat adults with desmoid tumors using nirogacestat; Provide therapy for NF1-PN patients with mirdametinib; Evaluate BCMA combination regimens in multiple myeloma; Offer expanded access programs for rare disease patients

SpringWorks Therapeutics primarily focuses on developing innovative medicines for rare tumors, hematological cancers, and biomarker-defined metastatic solid tumors. Their therapeutic areas include treatments for desmoid tumors and neurofibromatosis type 1, utilizing a precision oncology approach to create targeted therapies.

SpringWorks Therapeutics received the 2021 Innovation in Medicine Award at the Children's Tumor Foundation National Gala. This award recognizes the company's contributions to innovative medicine, particularly in the field of rare cancers.

SpringWorks Therapeutics primarily focuses on developing innovative medicines for rare tumors, hematological cancers, and biomarker-defined metastatic solid tumors. Their therapeutic areas include treatments for desmoid tumors and neurofibromatosis type 1, utilizing a precision oncology approach to create targeted therapies.

SpringWorks Therapeutics has developed key innovations in the biotech sector, particularly in oncology. Notable products include:

1. Nirogacestat: A gamma secretase inhibitor being evaluated in combination therapies for multiple myeloma.
2. Mirdametinib: An FDA-approved treatment for adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

The company focuses on rare oncology programs and biomarker-defined metastatic solid tumors, aiming to create best-in-class treatments for patients with devastating diseases.

SpringWorks Therapeutics has received regulatory approvals for the following products:

1. GOMEKLI™ (mirdametinib) - Approved by the FDA for the treatment of adult and pediatric patients with neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (NF1-PN). This approval was based on positive data from clinical trials showing significant tumor reduction.
2. OGSIVEO™ (nirogacestat) - Approved by the FDA as the first and only treatment for adults with desmoid tumors. This approval was granted on November 27, 2023.

The latest funding round for SpringWorks Therapeutics was a post-IPO round that took place on September 7, 2022, where the company raised $225 million. This round included participation from five investors, including EcoR1, Boxer Capital, Invus, Deerfield, and Perceptive Advisors.

SpringWorks Therapeutics has established several significant partnerships and collaborations in the biotech industry, including:

1. Rappta Therapeutics: In September 2023, SpringWorks entered into a global license agreement with Rappta Therapeutics for the development of a novel cancer treatment, RPT04402.

2. GSK (GlaxoSmithKline): SpringWorks had a collaboration with GSK for the combination of Nirogacestat with Blenrep, although this partnership was reported to be ending in early 2023.

3. AbbVie: SpringWorks announced a clinical collaboration with AbbVie to evaluate Nirogacestat in combination with ABBV-383.

4. Regeneron: A clinical trial collaboration and supply agreement was established with Regeneron to evaluate Nirogacestat in combination with REGN5458.

5. BeiGene: SpringWorks entered into a global clinical collaboration with BeiGene to evaluate targeted combination therapy in advanced solid tumors.

6. Pfizer: A clinical collaboration was announced with Pfizer to evaluate Nirogacestat in combination with PF-06863135.

7. Ab Magnitude: SpringWorks is collaborating with Ab Magnitude on target discovery and initial hit finding to advance next-generation oncology therapeutics.

These collaborations reflect SpringWorks' commitment to developing innovative therapies for rare cancers and serious diseases.

European Commission approved nirogacestat for desmoid tumors; Received positive CHMP opinion for nirogacestat; Conditional approval granted for mirdametinib in NF1-PN; Focus on rare oncology and BCMA combinations

SpringWorks Therapeutics received the 2021 Innovation in Medicine Award at the Children's Tumor Foundation National Gala. This award recognizes the company's contributions to innovative medicine, particularly in the field of rare cancers.

SpringWorks Therapeutics has established several significant partnerships and collaborations in the biotech industry, including:

1. Rappta Therapeutics: In September 2023, SpringWorks entered into a global license agreement with Rappta Therapeutics for the development of a novel cancer treatment, RPT04402.

2. GSK (GlaxoSmithKline): SpringWorks had a collaboration with GSK for the combination of Nirogacestat with Blenrep, although this partnership was reported to be ending in early 2023.

3. AbbVie: SpringWorks announced a clinical collaboration with AbbVie to evaluate Nirogacestat in combination with ABBV-383.

4. Regeneron: A clinical trial collaboration and supply agreement was established with Regeneron to evaluate Nirogacestat in combination with REGN5458.

5. BeiGene: SpringWorks entered into a global clinical collaboration with BeiGene to evaluate targeted combination therapy in advanced solid tumors.

6. Pfizer: A clinical collaboration was announced with Pfizer to evaluate Nirogacestat in combination with PF-06863135.

7. Ab Magnitude: SpringWorks is collaborating with Ab Magnitude on target discovery and initial hit finding to advance next-generation oncology therapeutics.

These collaborations reflect SpringWorks' commitment to developing innovative therapies for rare cancers and serious diseases.